In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy.
We report the selection of Clostridium difficile resistant to the rifamycin class of antibiotics in a patient within 32 h of receiving rifaximin for the treatment of recurrent C. difficile diarrhea. Resistance was associated with single nucleotide substitutions within rpoB.
TechLab, Inc., Blacksburg, Virginia, USA. rjcarman@techlab.com
Robert J
RJ
Carman
James H
JH
Boone
Harish
H
Grover
Kimberly N
KN
Wickham
Li
L
Chen
D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001426:Bacterial Proteins / Q000235:genetics* / Q000378:metabolism; D016360:Clostridioides difficile / Q000187:drug effects* / Q000235:genetics / Q000472:pathogenicity; D024881:Drug Resistance, Bacterial / Q000187:drug effects* / Q000235:genetics; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D020641:Polymorphism, Single Nucleotide; D012294:Rifamycins / Q000494:pharmacology / Q000627:therapeutic use*; D000078262:Rifaximin; D012641:Selection, Genetic
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D012294:Rifamycins; D000078262:Rifaximin